Antacids Market value was worth USD 16.0 billion in 2019 and estimated to be growing at a CAGR of 4.24%, to reach USD 19.7 billion by 2024.
Antacids are a group of medications that helps in neutralize the content of acid reflux in the stomach. It provides fast relief of heartburn, one of the main symptoms of gastroesophageal reflux digestion and other symptoms are nausea, bloating or belching. Antacids include magnesium carbonate, aluminum hydroxide, and magnesium trisilicate. Some people have reported allergic reactions to antacids. Antacids incorporate magnesium carbonate, aluminum hydroxide, and magnesium trisilicate. A few people have announced unfavorably susceptible responses to antacids.
Market Drivers
The growing trend toward self-medication is increasing the demand for over-the-counter digestive products for the treatment of gastrointestinal disorders. Antacids are used to neutralize acidity and should, therefore, cause a dramatic increase in demand. According to a study conducted by the American Gastroenterological Association and published in the International Functional Foundation in February 2017, about one-third of the US population. Suffering from GERD.
Key Challenges
Market restraints include some side effects such as constipation, laxative effect and allergic reactions. In addition, people suffering from certain medical conditions are prone to adverse effects that worsen their state of health because people with heart disease may have problems due to the high amount of sodium present in antacids.
Opportunities
Rise in the popularity for over the counter drugs through digital advertisements and campaigns is lucrative to surge growth opportunities for the market. Increasing prevalence to have treatment for gastrointestinal problems across the world is creating chances for the market to grow. The rise in the geriatric population is propelling the demand of the market as acidity complications show higher risk in aging people. Adoption of sedentary lifestyles also leads to several problems related to acidity. Growing demand for early diagnosis among individual is also expanding the growth of the market. Increasing focus on to release quality drugs along with high production rate is greatly influencing the demand of the market. Rising disposable income in urban areas is leveraging the growth of the antacids market. Also, the growing priority for self-medication is elevating the growth rate of this market to the extent. Growing awareness over the early symptoms of gastrointestinal diseases is also fueling the demand of the market.
This market research report on Global Antacids Market segmented and sub-segmented into the following categories and evaluated market size and forecast until 2024
Antacids Market Analysis – By Drug Class:
Among all, the Proton pump inhibitors segment led the market in 2018 and the trend is anticipated to continue in the forecast period. However, acid neutralizers segment emerge as a significant segment because of their extensive use in occasional heartburn and their availability range.
Antacids Market Analysis – By Formulation Type:
Tablet is the leading segment in 2018 and is anticipated to be the highest growing segment due to convenience in administration, low pricing and largely available.
Antacids Market Analysis – By Distribution Channel:
Other segments include online pharmacies and drug store which led the market segment. Rising adoption e-commerce and an increase in the number of online stores are boosting the growth of the market.
Antacids Market Analysis – By Disease Indications:
Antacids Market Analysis – By Region:
North America held the leading share in the overall market due to factors like the increasing number of gastro-oesophageal diseases and the growing geriatric population. Asia pacific stood second in contributing the market share. China and India are the key dominant regions due to improvements and healthcare services.
Antacids market in Europe is growing at a faster rate from the past few years and is also to continue the same flow in the coming years. It is segmented into Germany, UK, Italy, France and the rest of Europe. Germany is holding the highest shares of the market when compared with other countries. Germany- Increasing capital income is a major factor magnifying the demand of the market in this region. The rise in the consumption rate of drugs related to gastric problems is leveling up the growth of the market.
Most promising companies operating in the Global Antacids Market are:
Recent Market Developments:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.1 Introduction
5.1.2 Proton Pump Inhibitors
5.1.3 H2 Antagonist
5.1.4 Pro-motility agents
5.1.5 Acid Neutralizers
5.1.6 Y-o-Y Growth Analysis, By Drug Class
5.1.7 Market Attractiveness Analysis, Drug Class
5.1.8 Market Share Analysis, By Drug Class
5.2 Formulation Type
5.2.1 Introduction
5.2.2 Tablet
5.2.3 Liquid
5.2.4 Powder
5.2.5 Y-o-Y Growth Analysis, By Formulation Type
5.2.6 Market Attractiveness Analysis, By Formulation Type
5.2.7 Market Share Analysis, By Formulation Type
5.3 Distribution Channel
5.3.1 Introduction
5.3.2 Hospital Pharmacies
5.3.3 Retail pharmacies
5.3.4 Other
5.3.5 Y-o-Y Growth Analysis, By Distribution Channel
5.3.6 Market Attractiveness Analysis, By Distribution Channel
5.3.7 Market Share Analysis, By Distribution Channel
5.4 Disease Indications 5.4.1 Introduction
5.4.2 Cancer
5.4.3 CardiovascularDisorders
5.4.4 Neurological Disorders
5.4.5 Immunological Disorders
5.4.6 Other Diseases
5.4.7 Y-o-Y Growth Analysis, By Disease Indications
5.4.8 Market Attractiveness Analysis, By Disease Indications
5.4.9 Market Share Analysis, By Disease Indications
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Class
6.1.3.3 By Formulation Type
6.1.3.4 By Distribution Channel
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Class
6.1.4.3 By Formulation Type
6.1.4.4 By Distribution Channel
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Class
6.1.5.3 By Formulation Type
6.1.5.4 By Distribution Channel
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Glaxo Smith
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories
8.3 Pfizer Inc
8.4 Sun Pharmaceuticals
8.5 Consumer Health
8.6 Dabur
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
